INmune Bio Inc.

About INmune Bio Inc.

INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Their pipeline includes first-in-class therapies designed to maximize benefit without compromising safety, targeting neurologic disease and certain forms of cancer.

Products & Services

XPro1595:A therapy under development, with related publications available, likely targeting neurologic diseases or related conditions.

Pipeline Therapies:Innovative treatments being developed for neurologic diseases and certain forms of cancer, focusing on patient benefit and safety.

XPro1595

INKmune

Specialties

Innate Immune System Restoration Neurologic Disease Treatment Cancer Treatment Clinical Development for Patient Benefit matching drug mechanism of action to patient biology relevant clinical trial metrics progressive trial design anchored to patient outcomes

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 19000000 MR: - FA: approximately $19 million FAN: 19000000	D: 2025-06-30 FD: 2025-06-30	-
2	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 19000000 MR: - FA: approximately $19 million FAN: 19000000	D: 2025-06-27 FD: 2025-06-27	1 investors
3	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 13000000 MR: - FA: 13.0 million FAN: 13000000	D: 2024-09-13 FD: 2024-09-13	2 investors
4	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 9700000 MR: - FA: $9.7 million FAN: 9700000	D: 2024-04-25 FD: 2024-04-25	1 investors
5	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 4800000 MR: - FA: approximately $4.8 million FAN: 4800000	D: 2024-04-22 FD: 2024-04-22	1 investors
6	RT: Non-dilutive Funding (R&D Rebates) T: - FT: Non-dilutive Funding (R&D Rebates)	A: 6400000 MR: - FA: approximately $6.4 million FAN: 6400000	D: 2023-02-08 FD: 2023-02-08	2 investors

Registered Direct Offering Latest

2025-06-30

$19.0M

Registered Direct Offering 2025-06-27

$19.0M

Registered Direct Offering 2024-09-13

$13.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David J. Moss

CEO

D

David J. Moss

Director

M

Mark Lowdell

CSO/CMO

C

Christopher J. Barnum

Vice President of Neuroscience

J

Joshua S. Schoonover

General Counsel

T

Tara Lehner

Vice President of Clinical Operations

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

INmune Bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised